The FK506-binding protein 51 (FKBP51) plays an important role in the human stress response. In research funded by my ERC Starting Grant I identified the molecular mechanisms of how a de-repressed FKBP51 mediates stress- and trauma-induced risk for psychiatric disorders in genetically vulnerable individuals, thus validating FKBP51 as a potential drug target for stress-related disorders. The current proof-of-concept proposal aims at providing a due diligence analysis to support the concept that the development of FKBP51-directed drugs is technically feasible and economically warranted.
Call for proposal
See other projects for this call
Funding SchemeCSA-SA(POC) - Supporting action (Proof of Concept)